Cancer Treatment InnovationNXP900's data has been promising thus far, showing an ability to resensitize cancer cells to antitumor therapy.
Market OpportunityNSCLC is a significantly large market and patients who have developed ALK and EGFR inhibitor resistance have limited options.
Safety And TolerabilityPhase 1a results showed favorable tolerability and strong pathway suppression, leading to >90% SRC inhibition.